Abstract
GLP-1 and GIP receptor agonists are increasingly used in the management of T2DM and obesity due to their ability to stimulate insulin secretion, delay gastric emptying, and suppress appetite. The combination of GLP-1 and GIP agonism offers enhanced glycemic control and weight loss. Nevertheless, the advent of these novel therapies has also brought forth safety concerns, including cases of cholestatic hepatitis. The patient with obesity was prescribed a GLP-1/GIP dual receptor agonist as part of their treatment regimen. Shortly after 4 dose of therapy, the patient developed symptoms of severe cholestatic hepatitis, marked by jaundice and elevated liver enzymes. While hospitalized, no causes other than the medication were identified, and a liver biopsy conclusively diagnosed drug-induced cholestatic hepatitis. This represents the first documented case, and it is intended to draw global attention.